Data Supplement from Enhancing Reproducibility in Cancer Drug Screening: How Do We Move Forward?

Christos Hatzis,Philippe L. Bedard,Nicolai J. Birkbak,Andrew H. Beck, Hugo J.W.L. Aerts, David F. Stern,Leming Shi,Robert Clarke,John Quackenbush, Benjamin Haibe-Kains

crossref（2023）

引用 0|浏览1

暂无评分

摘要

Comparison of experimental protocols used in CGP and CCLE. Description of the major potential source of variability in phenotypic measurements between CGP and CCLE phenotype, due to differences in detection assay, quality assurance of screening plates, controls, and measures of drug potency (IC50).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要